Viking Therapeutics (VKTX)
(Delayed Data from NSDQ)
$56.23 USD
-6.04 (-9.70%)
Updated Jun 4, 2024 04:00 PM ET
After-Market: $56.85 +0.62 (1.10%) 7:22 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Brokerage Reports
0 items in cart
Viking Therapeutics, Inc. [VKTX]
Reports for Purchase
Showing records 21 - 40 ( 211 total )
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Clinical Development Momentum Builds Across Programs; Phase 2 VK2735 Obesity Study Expected 3Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Updates Show All Programs on Track; Reiterate Buy, $32 PT
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
EASL Congress 2023: Day 3 and Day 4 NASH Highlights
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
GLP1 Class Updates at ADA Create Opportunity for Investors
Provider: Roth Capital Partners, Inc.
Analyst: DUPUIS D
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pulling Its Weight Beyond NASH; Assuming at Buy, $32 PT
Provider: Roth Capital Partners, Inc.
Analyst: Research Department
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bon VOYAGE, Indeed!; VK2809 Phase 2b Trial Achieves Primary Endpoint
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Hitting the Sweet Spot; GLP-1 Therapies Are Shaking Up the Diabetes and Obesity Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2023 is Off to a Strong Start with Multiple Upcoming Shots on Goal; Price Target Increased to $33
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VK2735 Emerges as a Heavyweight Contender; Reiterate Top Pick
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Viking Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
VK2735 Early Obesity Data Compelling; PT to $19
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S